Aakash Desai/LinkedIn
Jan 9, 2025, 16:29
Aakash Desai: Rybrevant + Lazcluze to show clinically meaningful improvement in OS vs osimertinib
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared on X:
“MARIPOSA Johnson and Johnson announces Positive OS results in 1L EGFR
Amivantamab + lazertinib vs. osimertinib:
Statistically significant improvement in OS (press release states >1 yr survival benefit)
Await complete data and presentation.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 14, 2025, 06:56
Mar 14, 2025, 05:39
Mar 14, 2025, 05:30
Mar 14, 2025, 05:21
Mar 13, 2025, 14:26
Mar 13, 2025, 10:43
Mar 13, 2025, 10:14
Mar 13, 2025, 10:06
Mar 13, 2025, 09:32